These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30447706)

  • 1. Correlations of MicroRNA-21 Gene Polymorphisms With Chemosensitivity and Prognosis of Cervical Cancer.
    Zhang J; Li YH; Liu HL; Zhang Y; Zhang QS; Li SZ
    Am J Med Sci; 2018 Dec; 356(6):544-551. PubMed ID: 30447706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association study of relationships of polymorphisms in the miR-21, miR-26b, miR-221/222 and miR-126 genes with cervical intraepithelial neoplasia and cervical cancer.
    Yang J; Yan Z; Wang Y; Xu J; Li R; Li C; Liu S; Shi L; Yao Y
    BMC Cancer; 2021 Sep; 21(1):997. PubMed ID: 34488676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling.
    Xiong Y; Sun F; Dong P; Watari H; Yue J; Yu MF; Lan CY; Wang Y; Ma ZB
    J Exp Clin Cancer Res; 2017 Apr; 36(1):48. PubMed ID: 28399926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
    Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
    Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
    Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential molecular mechanisms for improved prognosis and outcome with neoadjuvant chemotherapy prior to laparoscopical radical hysterectomy for patients with cervical cancer.
    Sun H; Xin J; Lu Z; Wang N; Liu N; Guo Q
    Cell Physiol Biochem; 2013; 32(5):1528-40. PubMed ID: 24335178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study.
    Zhao H; Li L; Su H; Lin B; Zhang X; Xue S; Fei Z; Zhao L; Pan Q; Jin X; Xie C
    Oncotarget; 2016 Oct; 7(43):70969-70978. PubMed ID: 27391158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes.
    Shi TY; Cheng X; Yu KD; Sun MH; Shao ZM; Wang MY; Zhu ML; He J; Li QX; Chen XJ; Zhou XY; Wu X; Wei Q
    Carcinogenesis; 2013 Apr; 34(4):770-8. PubMed ID: 23299407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-1284 enhances sensitivity of cervical cancer cells to cisplatin via downregulating HMGB1.
    Chen J; Li G
    Biomed Pharmacother; 2018 Nov; 107():997-1003. PubMed ID: 30257412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
    Kitagawa R; Katsumata N; Shibata T; Kamura T; Kasamatsu T; Nakanishi T; Nishimura S; Ushijima K; Takano M; Satoh T; Yoshikawa H
    J Clin Oncol; 2015 Jul; 33(19):2129-35. PubMed ID: 25732161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity.
    Feng LL; Shen FR; Zhou JH; Chen YG
    Gene; 2019 May; 696():105-112. PubMed ID: 30738960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.
    Viñolas N; Provencio M; Reguart N; Cardenal F; Alberola V; Sánchez-Torres JM; Barón FJ; Cobo M; Maestu I; Moreno I; Mesía C; Izquierdo A; Felip E; López-Brea M; Márquez A; Sánchez-Ronco M; Tarón M; Santarpia MC; Rosell R;
    Lung Cancer; 2011 Feb; 71(2):191-8. PubMed ID: 20627363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
    Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
    Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study.
    Buda A; Fossati R; Colombo N; Fei F; Floriani I; Gueli Alletti D; Katsaros D; Landoni F; Lissoni A; Malzoni C; Sartori E; Scollo P; Torri V; Zola P; Mangioni C
    J Clin Oncol; 2005 Jun; 23(18):4137-45. PubMed ID: 15961761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
    Braicu EI; Fotopoulou C; Chekerov R; Richter R; Blohmer J; Kümmel S; Stamatian F; Yalcinkaya I; Mentze M; Lichtenegger W; Sehouli J
    Cytokine; 2013 Mar; 61(3):755-8. PubMed ID: 23415672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.
    Wen Q; Liu Y; Lyu H; Xu X; Wu Q; Liu N; Yin Q; Li J; Sheng X
    Int J Gynecol Cancer; 2017 Jul; 27(6):1096-1108. PubMed ID: 28472815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
    Karageorgopoulou S; Kostakis ID; Gazouli M; Markaki S; Papadimitriou M; Bournakis E; Dimopoulos MA; Papadimitriou CA
    BMC Cancer; 2017 Jun; 17(1):451. PubMed ID: 28659181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer: long-term results.
    Park DC; Suh MJ; Yeo SG
    Int J Gynecol Cancer; 2009 Jul; 19(5):943-7. PubMed ID: 19574789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
    Hong MJ; Lee SY; Choi JE; Jin CC; Kang HJ; Baek SA; Lee SY; Shin KM; Jeong JY; Lee WK; Yoo SS; Lee J; Cha SI; Kim CH; Son JW; Park JY
    Oncotarget; 2016 Mar; 7(13):15948-58. PubMed ID: 26893365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.
    Ferrandina G; Lauriola L; Distefano MG; Zannoni GF; Gessi M; Legge F; Maggiano N; Mancuso S; Capelli A; Scambia G; Ranelletti FO
    J Clin Oncol; 2002 Feb; 20(4):973-81. PubMed ID: 11844819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.